- Home
- HCM
as 01-17-2025 4:00pm EST
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
| Founded: | 2000 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.6B | IPO Year: | N/A |
| Target Price: | $19.00 | AVG Volume (30 days): | 76.1K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.93 - $21.92 | Next Earning Date: | 02-26-2025 |
| Revenue: | $610,806,000 | Revenue Growth: | -19.34% |
| Revenue Growth (this year): | -17.79% | Revenue Growth (next year): | 20.69% |
Latest HUTCHMED (China) Limited News
HCM Breaking Stock News: Dive into HCM Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Simply Wall St.
13 days ago
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week
TipRanks
16 days ago
Hutchmed divests 45% interest in Shanghai Hutchison for $608M
GlobeNewswire
17 days ago
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
GlobeNewswire
17 days ago
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
GlobeNewswire
a month ago
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
GlobeNewswire
a month ago
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
PR Newswire
a month ago
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
Compare HCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HCM HUTCHMED (China) Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.